APOE ε4 carrier frequency increased progressively from stable controls (15.8%) to MCI converters (40.0%) and AD patients (53.8%), in line with established epidemiological patterns, although these differences did not reach statistical significance, likely due to limited sample size (Table 2 ).
← all excerpts
Peripheral blood biomarkers RCAN1, Clusterin, RAGE, and malondialdehyde for early diagnosis and progression of Alzheimer's disease.
2
—
—
The sentences
RAGE levels showed a trend toward reduction in MCI but did not remain significant.